Antiphospholipid Syndrome — Written Clinical Reasoning · Phys Written Answers

Prompt

DCE-style written reasoning for Antiphospholipid Syndrome.

SAQ 1 — Integrated plan (12 marks)

Prompt: Provide a prioritised problem list and management sequence for this presentation. [1] [2]

Model Answer

1. Frame and red flags (3 marks) [1]

State the working diagnosis/syndrome, acuity, and what would force emergency treatment now. [1] [2]

2. Discriminating assessment (3 marks) [2]

List the key history, examination and investigations that separate dangerous differentials from benign mimics. [1] [2]

3. Treatment sequence (4 marks) [1] [3]

Immediate stabilisation, disease-specific therapy, monitoring, and complications prevention. [1] [2] [3]

4. Follow-up and communication (2 marks) [2]

Disposition, safety-net advice, and who owns follow-up. [1] [2]

SAQ 2 — Exam trap defence (8 marks)

Prompt: Name two high-yield traps in Antiphospholipid Syndrome and how you avoid them. [1] [2]

Model Answer

Trap one: delayed escalation of a high-risk feature — avoid by explicit red-flag checklist. [1]

Trap two: therapy mismatched to mechanism — avoid by confirming the discriminating test before escalating treatment. [2] [3]

References

[1]Vrotniakaite-Bajerciene K, Wang TF, Sabri E, Shorr R, et al. Recurrent VTE in patients with thrombophilia after stopping anticoagulation - A systematic review and meta-analysis Blood Adv, 2026.PMID 42448302
[2]Fang HS, Zhang XY, Liu XY, Chen HD, et al. Chromogenic factor X-guided warfarin monitoring in lupus anticoagulant-positive primary antiphospholipid syndrome with adrenal hemorrhage and progressive deep vein thrombosis: a case report J Med Case Rep, 2026.PMID 42437947
[3]Mohammadi A, Fattahi V Anesthesia in systemic lupus erythematosus: a review of key considerations and surgical challenges Perioper Med (Lond), 2026.PMID 42421133
[4]Esteban-Sampedro J, Martín-Portugués M, Ruiz-Irastorza G, Mellor-Pita S, et al. Impact of systemic autoimmune diseases in maternal, fetal and neonatal outcomes in Spain Rheumatology (Oxford), 2026.PMID 42421209
[5]Hidaka A, Kaneshige R, Nakamura S, Motoki Y, et al. Preliminary Evaluation of a Novel Lupus Anticoagulant Activity Assay Unaffected by Anticoagulants J Clin Lab Anal, 2026.PMID 42310902
[6]Ordieres-Ortega L, Galeano-Valle F, López-Rubio M, Alonso-Beato R, et al. Recurrent VTE During Anticoagulation: Diagnosis, Systematic Evaluation, and Management Chest, 2026.PMID 42264028
[7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
[8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922

SAQ 1 — Integrated plan (12 marks)

Prompt: Provide a prioritised problem list and management sequence for this presentation. [1] [2]

Model Answer

1. Frame and red flags (3 marks) [1]

State the working diagnosis/syndrome, acuity, and what would force emergency treatment now. [1] [2]

2. Discriminating assessment (3 marks) [2]

List the key history, examination and investigations that separate dangerous differentials from benign mimics. [1] [2]

3. Treatment sequence (4 marks) [1] [3]

Immediate stabilisation, disease-specific therapy, monitoring, and complications prevention. [1] [2] [3]

4. Follow-up and communication (2 marks) [2]

Disposition, safety-net advice, and who owns follow-up. [1] [2]

SAQ 2 — Exam trap defence (8 marks)

Prompt: Name two high-yield traps in Antiphospholipid Syndrome and how you avoid them. [1] [2]

Model Answer

Trap one: delayed escalation of a high-risk feature — avoid by explicit red-flag checklist. [1]

Trap two: therapy mismatched to mechanism — avoid by confirming the discriminating test before escalating treatment. [2] [3]

References

[1]Vrotniakaite-Bajerciene K, Wang TF, Sabri E, Shorr R, et al. Recurrent VTE in patients with thrombophilia after stopping anticoagulation - A systematic review and meta-analysis Blood Adv, 2026.PMID 42448302
[2]Fang HS, Zhang XY, Liu XY, Chen HD, et al. Chromogenic factor X-guided warfarin monitoring in lupus anticoagulant-positive primary antiphospholipid syndrome with adrenal hemorrhage and progressive deep vein thrombosis: a case report J Med Case Rep, 2026.PMID 42437947
[3]Mohammadi A, Fattahi V Anesthesia in systemic lupus erythematosus: a review of key considerations and surgical challenges Perioper Med (Lond), 2026.PMID 42421133
[4]Esteban-Sampedro J, Martín-Portugués M, Ruiz-Irastorza G, Mellor-Pita S, et al. Impact of systemic autoimmune diseases in maternal, fetal and neonatal outcomes in Spain Rheumatology (Oxford), 2026.PMID 42421209
[5]Hidaka A, Kaneshige R, Nakamura S, Motoki Y, et al. Preliminary Evaluation of a Novel Lupus Anticoagulant Activity Assay Unaffected by Anticoagulants J Clin Lab Anal, 2026.PMID 42310902
[6]Ordieres-Ortega L, Galeano-Valle F, López-Rubio M, Alonso-Beato R, et al. Recurrent VTE During Anticoagulation: Diagnosis, Systematic Evaluation, and Management Chest, 2026.PMID 42264028
[7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
[8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922